Journal Watch · Advanced Drug Delivery Reviews · 2026

Poly(2-oxazoline)s and poly(2-oxazine)s: An overview of stealth properties, pharmacokinetics, and immunogenicity.

This review aims to give an overview of the current status, which can be used as starting point for getting acquainted with poly(2-oxazoline)s as PEG-alternatives for those new to the field and as a source of inspiration for future research in the area.

Jana S, Hoogenboom RAdvanced Drug Delivery Reviews3 min readPharma relevance 70/100

DOI: 10.1016/j.addr.2026.115975PMID: 42822767Study type: review / perspective

TL;DR

This review aims to give an overview of the current status, which can be used as starting point for getting acquainted with poly(2-oxazoline)s as PEG-alternatives for those new to the field and as a source of inspiration for future research in the area.

Key findings

  • This review discusses the progress that has been made on poly(2-oxazoline)s as alternatives to PEG by discussing the state-of-the-art in poly(2-oxazoline) stealth/antifouling properties, pharmacokinetics, and immunogenicity, structured by polymer type, namely PMeOx, PEtOx, and other polymers, such as chiral poly(2-oxazoline)s and poly(2-oxazine)s.
  • This review aims to give an overview of the current status, which can be used as starting point for getting acquainted with poly(2-oxazoline)s as PEG-alternatives for those new to the field and as a source of inspiration for future research in the area.

What they did

Poly(2-oxazoline)s, particularly poly(2-methyl-2-oxazoline) (PMeOx) and poly(2-ethyl-2-oxazoline) (PEtOx), have emerged as promising PEG alternatives. Their hydrolytically stable amide backbone, absence of ether oxygens (key recognition motifs for anti-PEG antibodies), tunable hydrophilicity, chemical versatility, tailor-made properties and excellent antifouling characteristics position them as ideal stealth candidates.

Full abstract (original)

Background: For over four decades, poly(ethylene glycol) (PEG) has been the undisputed gold standard for conferring stealth properties to nanomedicines and polymer therapeutics. However, the widespread presence of pre-existing anti-PEG antibodies in the general population, which was intensified by recent mRNA COVID-19 vaccination campaigns, has exposed critical immunological liabilities, including accelerated blood clearance, hypersensitivity reactions and reduced therapeutic efficacy.

What they did: Poly(2-oxazoline)s, particularly poly(2-methyl-2-oxazoline) (PMeOx) and poly(2-ethyl-2-oxazoline) (PEtOx), have emerged as promising PEG alternatives. Their hydrolytically stable amide backbone, absence of ether oxygens (key recognition motifs for anti-PEG antibodies), tunable hydrophilicity, chemical versatility, tailor-made properties and excellent antifouling characteristics position them as ideal stealth candidates.

Results & conclusions: This review discusses the progress that has been made on poly(2-oxazoline)s as alternatives to PEG by discussing the state-of-the-art in poly(2-oxazoline) stealth/antifouling properties, pharmacokinetics, and immunogenicity, structured by polymer type, namely PMeOx, PEtOx, and other polymers, such as chiral poly(2-oxazoline)s and poly(2-oxazine)s. This review aims to give an overview of the current status, which can be used as starting point for getting acquainted with poly(2-oxazoline)s as PEG-alternatives for those new to the field and as a source of inspiration for future research in the area.

Abstract © the authors / Advanced Drug Delivery Reviews (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1016/j.addr.2026.115975 · PubMed 42822767.

Why it matters for pharma & biotech

  • Directly relevant to teams in mRNA / delivery technology, vaccines — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: mRNA / delivery technology · vaccines

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • As a review, this paper synthesises prior studies rather than reporting new experimental data; weight it accordingly.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Advanced Drug Delivery Reviews study find?

This review aims to give an overview of the current status, which can be used as starting point for getting acquainted with poly(2-oxazoline)s as PEG-alternatives for those new to the field and as a source of inspiration for future research in the area.

What type of study is this?

It is a review / perspective, published in Advanced Drug Delivery Reviews in 2026. Poly(2-oxazoline)s, particularly poly(2-methyl-2-oxazoline) (PMeOx) and poly(2-ethyl-2-oxazoline) (PEtOx), have emerged as promising PEG alternatives.

Where can I read the original paper?

The original is at the publisher via DOI 10.1016/j.addr.2026.115975. PubMed ID: 42822767. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Jana S, Hoogenboom R. Poly(2-oxazoline)s and poly(2-oxazine)s: An overview of stealth properties, pharmacokinetics, and immunogenicity.. Advanced Drug Delivery Reviews (2026). DOI: 10.1016/j.addr.2026.115975.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/poly-2-oxazoline-s-and-poly-2-oxazine-s-an-overview-of-stealth-propertie-115975/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides